T. Rowe Price Investment Management, Inc. Immunovant, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,331,017 shares of IMVT stock, worth $91.6 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
3,331,017
Previous 1,625,220
104.96%
Holding current value
$91.6 Million
Previous $42.9 Million
121.34%
% of portfolio
0.06%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding IMVT
# of Institutions
209Shares Held
66.6MCall Options Held
2.11MPut Options Held
451K-
Vanguard Group Inc Valley Forge, PA6.66MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.35MShares$120 Million4.41% of portfolio
-
Armistice Capital, LLC New York, NY3.55MShares$97.6 Million1.62% of portfolio
-
State Street Corp Boston, MA3.02MShares$83.1 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...